Paroxysmal Nocturnal Hemoglobinuria News and Research

RSS
Alexion second quarter net product sales increase to $274.7 million

Alexion second quarter net product sales increase to $274.7 million

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Almac collaborates with Alexion for packaging and distribution of Soliris during German E. coli outbreak

Almac collaborates with Alexion for packaging and distribution of Soliris during German E. coli outbreak

Alexion third quarter total revenues increase to $204.0 million

Alexion third quarter total revenues increase to $204.0 million

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

All Canadian provinces except Quebec announce funding agreement for PNH drug, Soliris

All Canadian provinces except Quebec announce funding agreement for PNH drug, Soliris

Alexion second quarter net product sales of Soliris increase to $185.7 million

Alexion second quarter net product sales of Soliris increase to $185.7 million

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

Alexion first quarter non-GAAP net income increases to $56.3 million

Alexion first quarter non-GAAP net income increases to $56.3 million

Blood journal to publish Soliris study results in Paroxysmal Nocturnal Haemoglobinuria

Blood journal to publish Soliris study results in Paroxysmal Nocturnal Haemoglobinuria

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Alexion fourth quarter net product sales of Soliris increases to $156.0 million

Alexion fourth quarter net product sales of Soliris increases to $156.0 million

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

New analysis evaluates association between hemolysis, mortality in patients with PNH

New analysis evaluates association between hemolysis, mortality in patients with PNH

New data on Soliris for PNH treatment to be presented at ASH Annual Meeting

New data on Soliris for PNH treatment to be presented at ASH Annual Meeting

Alexion 2010 third quarter revenue increases from $102.6 to $141.6 million

Alexion 2010 third quarter revenue increases from $102.6 to $141.6 million

Dr. Bessler joins Children's Hospital of Philadelphia

Dr. Bessler joins Children's Hospital of Philadelphia

USPTO grants Taligen patent for TT30 lead product candidate

USPTO grants Taligen patent for TT30 lead product candidate

Taligen Therapeutics announces closing on $10M tranche of Series B financing

Taligen Therapeutics announces closing on $10M tranche of Series B financing